10x Genomics Announces Preliminary Q4 Revenue $184M vs $179.7M Est., Prelim. 2023 Revenue $618.7M vs $614.69M Est.
Portfolio Pulse from Benzinga Newsdesk
10x Genomics has announced preliminary Q4 revenue of $184M, surpassing the estimate of $179.7M. Additionally, the company's preliminary revenue for 2023 is reported at $618.7M, which also exceeds the estimated $614.69M.
January 08, 2024 | 2:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
10x Genomics reported higher-than-expected preliminary Q4 revenue and also projected higher revenue for 2023, indicating strong financial performance and potential growth.
The positive preliminary revenue figures for both Q4 and the full year 2023 suggest that 10x Genomics is performing better than analysts expected, which is likely to instill confidence in investors and could lead to a short-term increase in the stock price. The announcement directly pertains to the company's financial health and future outlook, making it highly relevant and important to investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100